Biochemical markers in ovarian cancer
Kiricuta, I.; Bojan, O.; Munteanu, S.
Archiv für Geschwulstforschung 56(1): 35-38
1986
ISSN/ISBN: 0003-911X PMID: 3964031 Document Number: 284834
Fucose and sialic acid were measured in 41 patients with malignant ovarian tumors and in 25 patients with benign tumors. Supplementary, serial determinations done in 20 patients, with advanced ovarian cancer subjected to primary or secondary surgery (optimal tumor debulking) and subsequent chemotherapy enables to suggest the possibility to use these parameters as markers in monitoring ovarian cancer evolution and treatment.
Document emailed within 1 workday
Related Documents
Nozawa, S.; Udagawa, Y.; Sasaki, H.; Ito, K.; Akiya, K.; Terashima, Y.; Takamizawa, H.; Ohkura, H.; Fujimoto, S.; Hashimoto, M. 1992: Studies of clinical usefulness of new tumor markers of ovarian cancer, CA 54/61 and CA 602--CA 602 assay reagent kit, performance its normal value and correlations with other tumor markers Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(12): 2085-2093Ho, S.B.; Toribara, N.W.; Bresalier, R.S.; Kim, Y.S. 1988: Biochemical and other markers of colon cancer Gastroenterology Clinics of North America 17(4): 811-836
Gargano, G.; Correale, M.; Abbate, I.; Falco, G.; De Frenza, N.; Lorusso, V.; De Lena, M.; De Leonardis, A. 1990: The role of tumour markers in ovarian cancer Clinical and Experimental Obstetrics and Gynecology 17(1): 23-29
Xu, S.X. 1990: Tumor markers in the monitoring of ovarian cancer Zhonghua Fu Chan Ke Za Zhi 25(6): 345-347; 383
Sparholt, M.H.; Høgdall, E.; Høgdall, C.K. 2009: Tumour markers in epithelial ovarian cancer Ugeskrift for Laeger 171(48): 3505-3509
Kizawa, I.; Kikuchi, Y.; Kato, K. 1983: Diagnostic value of biochemical tumor markers in serum of patients with cancer of the ovary Nihon Sanka Fujinka Gakkai Zasshi 35(3): 251-258
Li, L.; Yang, Z.J.; Wang, Q. 2017: Current status and future of epithelial ovarian cancer markers Zhonghua Fu Chan Ke Za Zhi 52(1): 4-7
Yamauchi, M. 2009: Biochemical markers of bone turnover. new aspect. Biochemical bone markers of bone in patients treated with glucocorticoid Clinical Calcium 19(8): 1092-1100
Fukuyama, A.; Yokoyama, Y.; Wada, J.; Hashimoto, T.; Oda, T.; Sato, S.; Mizunuma, H. 2009: Two cases of ovarian cancer at an early stage incidentally detected using transvaginal ultrasonography in screening: importance of interval for ovarian cancer screening and selection of population with a high risk of ovarian cancer European Journal of Gynaecological Oncology 30(2): 208-210
Kanoh, Y. 2011: Biochemical markers and physiological tests of atherosclerosis--changes and usefulness of markers in anti-atherosclerotic therapy Rinsho Byori. Japanese Journal of Clinical Pathology 59(1): 80-88
Hartge, P.; Hayes, R.; Reding, D.; Sherman, M.E.; Prorok, P.; Schiffman, M.; Buys, S. 2000: Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the prostate, lung, colon, and ovarian cancer screening trial American Journal of Obstetrics and Gynecology 183(5): 1232-1237
Demeter, A.; Sziller, I.; Csapo, Z.; Olah, J.; Keszler, G.; Jeney, A.; Papp, Z.; Staub, M. 2005: Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer Anticancer Research 25(4): 2885-2889
Kuroda, I.; Ueno, M. 2009: Biochemical markers of bone turnover. new aspect. Bone metabolic markers in prostatic carcinoma Clinical Calcium 19(8): 1170-1177
Kolberg, H.C.; Villena-Heinsen, C.; Deml, M.M.; Kraemer, S.; Diedrich, K.; Friedrich, M. 2005: Relationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude mice European Journal of Gynaecological Oncology 26(4): 398-402
Suzuki, M.; Sekiguchi, I.; Tamada, T.; Sakurabayashi, I.; Kawai, T. 1985: Clinical evaluation of a cancer antigen CA125 associated with ovarian cancer. (III) Serum CA125 levels in patients with ovarian cancer and other gynecological tumors Rinsho Byori. Japanese Journal of Clinical Pathology 33(2): 173-177
Rose, P.G.; Hunter, R.E. 1994: Advanced ovarian cancer in a woman with a family history of ovarian cancer, discovered at referral for prophylactic oophorectomy. A case report Journal of Reproductive Medicine 39(11): 908-910
Tanaka, K. 1989: Ovarian cancer--assessment of methods for cytogenetic analysis and chromosome aberrations found in ovarian cancer Rinsho Byori. Japanese Journal of Clinical Pathology Spec no 80: 268-280
Du Bois, A.; Lück, H.J.; Meier, W.; Möbus, V.; Costa, S.; Richter, B.; Warm, M.; Bauknecht, T.; Schröder, W.; Olbricht, S.; Nitz, U.; Jackisch, C. 1997: Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase IIi trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group Seminars in Oncology 24(5 Suppl 15: S15
Chou, Y-Ching.; Chen, Y-Jen.; Lai, C-Ru.; Wang, P-Hui.; Hsin-Chan; Yuan, C-Chung. 2006: Cyclooxygenase-2 expression is higher in ovarian cancer tissue adjacent to endometriosis than in ovarian cancer without comorbid endometriosis European Journal of Obstetrics Gynecology and Reproductive Biology 124(1): 101-105
Hashimoto, T.; Abe, M.; Matsumoto, T. 2004: Biochemical markers in bone metastasis Gan to Kagaku Ryoho. Cancer and ChemoTherapy 31(7): 1027-1033